These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 26288118)

  • 41. A drug safety evaluation of mirabegron in the management of overactive bladder.
    Robinson D; Thiagamoorthy G; Cardozo L
    Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase II dose-ranging study of mirabegron in patients with overactive bladder.
    Chapple CR; Dvorak V; Radziszewski P; Van Kerrebroeck P; Wyndaele JJ; Bosman B; Boerrigter P; Drogendijk T; Ridder A; Van Der Putten-Slob I; Yamaguchi O;
    Int Urogynecol J; 2013 Sep; 24(9):1447-58. PubMed ID: 23471546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ; Chapple C; Esen AA; Athanasiou S; Cambronero J; Mitcheson D; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Herholdt C; MacDiarmid S;
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.
    Herschorn S; Staskin D; Schermer CR; Kristy RM; Wagg A
    Drugs Aging; 2020 Sep; 37(9):665-676. PubMed ID: 32725584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
    Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
    Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.
    Hsiao SM; Chang TC; Chen CH; Wu WY; Lin HH
    Low Urin Tract Symptoms; 2018 Sep; 10(3):215-220. PubMed ID: 28436145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study.
    Frankel J; Varano S; Staskin D; Shortino D; Jankowich R; Mudd PN
    Int J Clin Pract; 2021 May; 75(5):e13937. PubMed ID: 33332699
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?
    Yamanishi Y; Yamanishi T; Tajima H; Ikeda S
    Int J Urol; 2018 Oct; 25(10):863-870. PubMed ID: 30112772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mirabegron: A Review in Overactive Bladder Syndrome.
    Deeks ED
    Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
    Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
    Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.
    Bunniran S; Davis C; Kristy R; Ng D; Schermer CR; Uribe C; Suehs BT
    Neurourol Urodyn; 2018 Jan; 37(1):177-185. PubMed ID: 28370541
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison.
    Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z
    Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
    Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
    BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
    Caremel R; Loutochin O; Corcos J
    Int Urogynecol J; 2014 Feb; 25(2):165-70. PubMed ID: 23922008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.